Last reviewed · How we verify
IVT PCV-25
At a glance
| Generic name | IVT PCV-25 |
|---|---|
| Sponsor | Inventprise Inc. |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Dose-Ranging Study to Evaluate a 25-Valent Pneumococcal Conjugate Vaccine (PHASE2)
- Phase 2 Trial to Evaluate Safety and Immunogenicity of Inventprise's (IVT) 25-valent Pneumococcal Conjugate Vaccine (IVT PCV-25) in Healthy Infants (PHASE2)
- Study to Evaluate a 25-Valent Pneumococcal Conjugate Vaccine (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IVT PCV-25 CI brief — competitive landscape report
- IVT PCV-25 updates RSS · CI watch RSS
- Inventprise Inc. portfolio CI